

Mortality associated with influenza infections in France before and during the COVID-19 pandemic, and mortality associated with Omicron infections, including mortality for cardiovascular disease and for mental and behavioral disorders

Author: Edward Goldstein

Harvard Medical School, Boston, MA 02114, USA edmigo3@gmail.com

Abstract

Background: There is limited information on mortality associated with influenza and Omicron infections, as infections with those viruses are often not detected, or listed as contributing causes of death. **Methods:** We applied the previously developed methodology to estimate the contribution of influenza infections to all-cause mortality in France for the 2014-2015 through the 2018-2019 influenza seasons, and the contribution of both SARS-CoV-2 and influenza infections to all-cause mortality between week 33, 2022 through week 12, 2023. **Results:** For the 2014-2015 through the 2018-2019 seasons, influenza was associated with an average of 15654 (95% CI (13013,18340)) deaths, while between week 33, 2022 through week 12, 2023, we estimated 7851 (5213,10463) influenza-associated deaths and 32607 (20794,44496) SARS-CoV-2 associated deaths. The number of SARS-CoV-2-associated deaths during the Omicron epidemic was significantly higher than the number of deaths with COVID-19 listed on the death certificate or the hospitalization record – for example, between weeks 33-52 in 2022, we estimated 23983 (15307,32620) SARS-CoV-2-associated deaths in France, compared with 12811 deaths with COVID-19 listed on the death certificate, and 8639 in-hospital deaths with COVID-19 during the same period. While we do not have cause-specific mortality data for France, in the US, compared to the SAR-CoV-2 epidemic in the Fall-Winter of 2021-2022, for the first Omicron epidemic wave in 2022 there were significantly higher increases in mortality with

cardiovascular disease, as well as with mental/behavioral disorders listed on the death certificate and COVID-19 NOT listed on the death certificate, and smaller increases (compared to the 2020-2021 epidemic) in mortality with either cardiovascular disease or mental/behavioral disorders and COVID-19 listed on the death certificate. **Conclusions:** The relatively high levels of mortality associated with Omicron infections (including deaths with COVID-19 not listed on the death certificate) suggest the need for wider detection/treatment of Omicron infections (particularly in individuals with underlying health conditions such as mental/behavioral disorders and cardiac disease), as well as for an increase in COVID-19 booster vaccination coverage in different population groups (including non-elderly individuals) to mitigate SARS-CoV-2 transmission in the community. Our results also suggest the need for boosting influenza vaccination coverage in different population groups (including children) in France to mitigate influenza transmission in the community, and for wider testing for influenza infection in respiratory hospitalizations (including pneumonia) in high-risk individuals during influenza seasons in combination with the use of influenza antiviral medications.

Introduction

With the emergence of the Omicron variant of SARS-CoV-2, it became clear that the relative risk for complications, including hospital admission and death in adults is lower for the Omicron variant compared to the Delta variant, though those relative risks vary with age, with the relative risk for severe outcomes, including death for Omicron vs. Delta being greatest for the oldest adults [1,2]. At the same time, appearance of the Omicron variant led to an increase in the proportion of severe outcomes (including hospitalizations and ICU admissions) in SARS-CoV-2-positive patients that were for a cause other than COVID-19 – see for example the data from France on hospitalizations and ICU admissions with a SARS-CoV-2 infection for a cause other than COVID-19 vs. admissions for COVID-19 [3]. This is related to differences in disease manifestation for Omicron infections vs. Delta infections for both emergency department (ED) admissions [4], hospitalizations [5], and admissions to critical care [6]. In particular, Omicron epidemics make a substantial contribution to mortality for cardiac causes, cancer, Alzheimer’s disease/neurological disorders, and other causes [7].

In December 2022, high rates of all-cause mortality, not seen since April 2020, were recorded in France [8]. Those high rates of excess all-cause mortality were related to the Omicron and the influenza epidemics during this period, with levels of excess all-cause mortality during the peak of the Omicron epidemic being much higher compared to the rates of deaths with COVID-19 [3]. Moreover, data on the place of death suggests that the greatest relative increases in mortality in the 2nd half of December 2022 in France took place in long-term care facilities for older individuals [9]. Those increases in mortality, particularly during the periods of the Omicron epidemic waves, suggest the need to better understand the contribution of Omicron and influenza infections to mortality for different principal causes of death in France. For influenza, only a fraction of influenza-associated mortality has respiratory diseases as an underlying cause of death [10-12], with an additional significant contribution of influenza infections to mortality for circulatory and other non-respiratory causes [10,12,13]. Despite the high rates of influenza-associated mortality, frequency of testing for influenza and the related use of antiviral medications may be relatively low for various illness episodes (including pneumonia hospitalizations) during periods of active influenza circulation in the community. A US study found that frequency of testing for influenza in cases of community-acquired pneumonia (CAP) in the US had increased significantly between 2010-2015, whereas oseltamivir use on the first day of hospitalization in influenza-positive cases was associated with a relative risk of 0.75; 95% CI, 0.59-0.96 for 14-day in-hospital mortality [14]. Analogous data for other countries, including France, should be useful for informing guidelines on testing and treating influenza infections in respiratory illness episodes, including pneumonia, particularly in high-risk individuals.

In addition to wider detection/treatment of Omicron and influenza infections, particularly in older individuals/persons with underlying health conditions, boosting vaccination coverage for both SARS-CoV-2 and influenza should help mitigate the spread of those infections in the community and the associated burden of severe outcomes, including deaths. Vaccination coverage for the 2nd booster for COVID-19 in France is largely restricted to persons aged over 60y [15]. At the same time, there is evidence that vaccination reduces both the risk of acquisition of Omicron infections [16], as well as the risk of onward transmission of infection [17]. For influenza, vaccination coverage levels in different population groups in France are moderate-to-

low [18], and lower than influenza vaccination coverage levels in the corresponding population groups in the US [19]. This pertains to both influenza vaccination coverage in risk groups for influenza-associated complications, as well as to population groups that play an important role in spreading influenza infections in the community. In particular, studies have found that children experience higher than average influenza infection rates [20] and play an important role in the spread of influenza infection in different countries [21], including France [22].

In our earlier work [10,12], we developed a method for combining data on syndromic surveillance with data on virologic surveillance to estimate rates of mortality associated with the major influenza subtypes in the US. Subsequently, this method was applied to the estimation of influenza-associated mortality in other countries [23-25], including the EU population [25]. Here we adopt this framework to evaluate the contribution of influenza infections to all-cause mortality for the 2014-2015 through the 2018-2019 influenza seasons in France, as well as the contribution of SARS-CoV-2 and influenza infections to all-cause mortality in France between week 33, 2022 through week 12, 2023. The reason for omitting the period between 2020 through August 2022 from the analyses is that patterns of non-COVID-19 mortality have changed during the pandemic due to lockdowns, disruption in the circulation of other respiratory viruses [26] and other factors. For example, examination of mortality in England and Wales between March 2020 and June 2022 suggested that for deaths for which COVID-19 wasn't coded as the underlying cause of death, there was a reduction of 36,7000 in the number of deaths for respiratory causes compared to averages during the previous 5 years [27]. Additionally, the heat wave in France resulted in significant levels of excess mortality in July 2022 [28]. However, starting mid-August 2023, baseline rates of mortality not associated with SARS-CoV-2 or influenza infections in France have returned to more regular patterns, which allowed for the inclusion of the period starting mid-August 2022 into the inference model developed in [10,12] to evaluate the contribution of influenza and SARS-CoV-2 infection to all-cause mortality in France. In addition to all-cause mortality data in France, we also examined data on US mortality with cardiovascular disease, as well as mortality with mental/behavioral disorders listed on the death certificate, with each of those data streams further stratified by having COVID-19 listed, or not listed on the death certificate [29]. The aim of that analysis was to examine how SARS-CoV-2 epidemic waves affected mortality for cardiac disease, and for mental/behavioral disorders, including

mortality with COVID-19 not listed on the death certificate. The overall aim of this work is to help inform vaccination policies for SARS-CoV-2 and influenza, and policies for detecting/treating SARS-CoV-2 and influenza infections, particularly in persons with underlying health conditions.

Methods

Data availability

This manuscript is based on aggregate, de-identified publicly available data that can be accessed through refs. [8,29-33]. Data on weekly numbers of influenza-like illness (ILI) consultations in metropolitan France are available from the French sentinel surveillance [30]. Sentinel data on testing of respiratory specimens for the different influenza subtypes (A/H1N1, A/H3N2, B/Victoria and B/Yamagata) are available from WHO FluNET [31]. Data on the daily number of deaths in France starting 2015 are available from [8]. Data on population in France are available from [32]. Electronic records for deaths with COVID-19 listed on the death certificate are available from [33]. We note that many SARS-CoV-2-associated deaths are not listed in [33], and weekly death rates in [33] are used as a covariate in the regression model rather than the estimate of the contribution of COVID-19, or SARS-CoV2 infections to mortality. Finally, data on US mortality with different contributing causes are available from [29].

Incidence indicators for the major influenza subtypes, and for SARS-CoV-2-associated deaths

Not all influenza-like illness (ILI) consultations in the sentinel data [30] correspond to influenza infections, and those that do, correspond to infection with different influenza subtypes. For each influenza subtype (e.g. A/H3N2), we define an indicator for the incidence of that subtype on week t (e.g. $A/H3N2(t)$) as

$$A/H3N2(t) = \text{Rate of ILI consultations per 100,000 persons on week } t \text{ in [30]} * \text{Percent of respiratory specimens on week } t \text{ in [31] positive for influenza A/H3N2} \quad (1)$$

To relate the incidence indicators for the major influenza subtypes to weekly levels of all-cause mortality per 100,000 persons in France [8], we note that age distribution of influenza cases changes with the appearance of antigenically novel influenza strains, and this changes the relation between rates of influenza-associated ILI (incidence indicators in eq. 1) and rates of influenza-associated mortality. The relevant antigenic changes for our study period were (a) the appearance of an antigenically/genetically novel A/H3N2 strain during the 2014-2015 influenza season [34]; the appearance of the novel influenza B/Yamagata strain during the 2017-2018 season [25]; the 2018-2019 A/H3N2 epidemic strains belonging to several clades and exhibiting different immunity profiles for different birth cohorts [35]. Correspondingly, for the model relating A/H3N2 circulation to associated mortality, we split the A/H3N2 incidence indicator into three: $A/H3N2_1$, equaling the A/H3N2 incidence indicator for the period from Jan. 2015 to Sep. 2015, and equaling to 0 for later weeks; $A/H3N2_2$, equaling the A/H3N2 incidence indicator for the period from Oct. 2015 to Sep. 2018, and equaling to 0 for other weeks, and $A/H3N2_3$, equaling the A/H3N2 incidence indicator for the period starting Oct. 2018, and equaling to 0 for other weeks. Similarly, we split the B/Yamagata incidence indicator into two, corresponding to the periods before and starting the 2017-2018 B/Yamagata epidemic. Finally, we note that it takes 1-2 weeks between influenza illness and influenza-associated mortality [10]. Correspondingly, we use a regression framework (eq. 2 below) to relate the mortality rate $M(t)$ on week t to the *shifted* incidence indicators, e.g.

$$A/H3N2^s(t) = s \cdot A/H3N2(t - 2) + (1 - s) \cdot A/H3N2(t - 1)$$

where the parameter s (common for all incidence indicators) is chosen to minimize the R-squared for the model fit. For the estimation of the rates of SARS-CoV-2-associated deaths, we use the weekly rates $Cov_e(t)$ of deaths with COVID-19 listed on the electronic death certificate in [33] as an indicator (covariate in the regression model).

Regression model: The regression model that we use is:

$$M(t) = \beta_1 \cdot A/H1N1^s(t) + \beta_2 \cdot A/H3N2_1^s(t) + \beta_3 \cdot A/H3N2_2^s(t) + \beta_4 \cdot A/H3N2_3^s(t) + \beta_5 \cdot B/Victoria^s(t) + \beta_6 \cdot B/Yamagata_1^s(t) + \beta_7 \cdot B/Yamagata_2^s(t) + \beta_8 \cdot Cov_e(t) + Baseline(t) + Trend(t) + Noise \quad (2)$$

The time period that we include in the analysis is week 3, 2015 through week 2, 2020, and week 33, 2022 through week 12, 2023. The baseline represents weekly rates of mortality not associated with influenza or SARS-CoV-2 circulation, and $Baseline(t)$ is modelled to have annual periodicity in week t . We use periodic cubic splines to model the baseline mortality rates whose shape is unknown [10,12]. The trend $Trend(t)$ is modelled as a quadratic polynomial in week t . Finally, to account for the autocorrelation in the noise, we use a bootstrap procedure (resampling the noise on different weeks) to estimate the confidence bounds for various quantities evaluated in the model [10].

US mortality: We use data on US mortality with cardiovascular disease (ICD-10 I00-I99), as well as mortality with mental/behavioral disorders (ICD-10 F01-F99) listed on the death certificate, with each of those data streams further stratified by having COVID-19 (ICD-10 U07.1) listed, or not listed on the death certificate [29].

Results

France mortality data

Figure 1 plots the results of the regression model in eq. 2. Figure 1 suggests that the model fits is generally temporally consistent, with baseline rates of non-influenza mortality + trend + the contribution of influenza infections to all-cause mortality (difference between the red and the green curves) explaining the patterns of mortality prior to the COVID-19 pandemic, while baseline + trend + contribution of influenza infections + contribution of SARS-CoV-2 infections to mortality explaining the patterns of mortality between week 33, 2022 and week 12, 2023 (with SARS-CoV-2 infections being responsible for most of excess mortality during that period).

Weekly mortality per 100,000 persons in France, model fit and the contribution of influenza and SARS-CoV-2 to mortality




Figure 1: Weekly mortality rates for all causes between week 3, 2015 through week 2, 2020, and week 33, 2022 through week 12, 2023 (black curve), the baseline + trend for the rates of mortality not associated with influenza or SARS-CoV-2 infections in France (green curve), the model fit (baseline + trend + contribution of influenza infection + contribution of SARS-CoV-2 infection to mortality, red curve), and the model fit between week 33, 2022 through week 12, 2023 with the contribution of SARS-CoV-2 infection removed.

Table 1 gives the estimates of the contribution of influenza infections to all-cause mortality for the 2014-2015 through the 2018-2019 influenza seasons, and the contribution of SARS-CoV-2 and influenza infections to all-cause mortality between week 33, 2022 through week 12, 2023. For the 2014-2015 through the 2018-2019 seasons, influenza was associated with an average of 15654 (95% CI (13013,18340)) deaths, while between week 33, 2022 through week 12, 2023, we estimated 7851 (5213,10463) influenza-associated deaths and 32607 (20794,44496) SARS-CoV-2 associated deaths.

Season	Influenza-associated deaths	SARS-CoV-2-associated deaths
2014-2015	19779 (15438,24122)	
2015-2016	5432 (902,9932)	
2016-2017	21997 (17891,26067)	
2017-2018	19138 (13599,24838)	
2018-2019	11925 (8632,15245)	
Annual average, 2014-2015 through 2018-2019 seasons	15654 (13013,18340)	
Week 33, 2022 – Week 12, 2023	7851 (5213,10463)	32607 (20794,44496)

Table 1: The contribution of influenza infection to all-cause mortality for the 2014-2015 through the 2018-2019 influenza seasons, and the contribution of SARS-CoV-2 and influenza infections to all-cause mortality between week 33, 2022 through week 12, 2023.

Data on mortality with COVID-19 listed on the death certificate in France are available through the end of 2022 [33]. For the period between weeks 33-52 in 2022, we estimated 23983 (15307,32620) SARS-CoV-2-associated deaths in France, compared with 12811 deaths with COVID-19 listed on the death certificate [33], and 8639 in-hospital deaths with COVID-19 during the same period [36].

US mortality data

Figure 2 plots the weekly number of US deaths with a cardiac cause but without COVID-19 listed on death certificate, as well as the number of deaths with both a cardiac cause and COVID-19 listed on the death certificate between Nov. 21, 2020—Nov. 19, 2022. Figure 3 plots the weekly number of US deaths with mental/behavioral disorders but without COVID-19 listed on death certificate, as well as the number of deaths with both mental/behavioral disorders and COVID-19 listed on the death certificate between Nov. 21, 2020—Nov. 19, 2022. Figures 2 and 3 suggest that compared to the SAR-CoV-2 epidemic in the Fall-Winter of 2021-2022, for the first Omicron epidemic wave in 2022 there were significantly higher increases in mortality with cardiovascular disease, as well as in mortality with mental/behavioral disorders listed on the

death certificate and COVID-19 NOT listed on the death certificate, and smaller increases (for the first Omicron epidemic wave compared to the 2020-2021 epidemic) in mortality with either cardiovascular disease and COVID-19 listed on the death certificate, or with mental/behavioral disorders and COVID-19 listed on the death certificate.




Figure 2: Weekly US deaths with a cardiac cause but without COVID-19 on death certificate and deaths with a cardiac cause and COVID-19 on death certificate, Nov. 21, 2020—Nov. 19, 2022




Figure 3: Weekly US deaths with mental/behavioral disorders but without COVID-19 on death certificate and deaths with mental/behavioral disorders and COVID-19 on death certificate, Nov. 21, 2020—Nov. 19, 2022

Discussion

During the winter of 2022-2023, high levels of excess mortality (not seen since the 1st COVID-19 wave in April 2020) were recorded in France [8], with excess mortality being primarily associated with the Omicron epidemic [3], but also the influenza epidemic during that period [37]. The emergence of the Omicron variant saw a higher proportion of ICU admissions and deaths with a SARS-CoV-2 infection which were for causes other than COVID-19 compared to the earlier SARS-CoV-2 variants [3]. Additionally, most influenza-associated deaths do not have influenza listed on the death certificate [10,12]. A better understanding is required of the

contribution of SARS-CoV-2 and influenza infections to hospitalizations and mortality to inform vaccination policies for SARS-CoV-2 and influenza, and policies for detecting/treating SARS-CoV-2 and influenza infections, particularly in persons with underlying health conditions.

For the period between weeks 33-52 in 2022, we estimated 23983 (15307,32620) SARS-CoV-2-associated deaths in France, compared with 12811 deaths with COVID-19 listed on the death certificate, and 8639 in-hospital deaths with COVID-19 during the same period. A significant contribution of Omicron infections to mortality for cardiac causes, cancer, Alzheimer's disease/neurological disorders and other causes was also found in [7]. Data on US mortality examined in this paper also suggests a significant burden of excess deaths for cardiac disease and for mental/behavioral disorders without COVID-19 listed on the death certificate during the Omicron epidemic wave in 2022. Those findings suggest the need to widen the detection/treatment of Omicrons infections, particularly in individuals with underlying health conditions, as well as the need to increase COVID-19 booster vaccination coverage in the whole population to mitigate SARS-CoV-2 transmission in the community. We have also estimated that influenza was responsible for high levels of associated mortality prior to the pandemic, with an average of 15654 (95% CI (13013,18340)) deaths associated with influenza infections during the 2014-2015 through the 2018-2019 seasons, as well as 7851 (5213,10463) influenza-associated deaths between week 33, 2022 through week 12, 2023. Influenza vaccination coverage in non-elderly individuals in France is significantly lower compared to the US [18,19], with children known to play a significant role in influenza transmission in the community [20-22]. Additionally, influenza vaccine effectiveness in older individuals can be quite low [38], and types of influenza vaccines administered to older individuals play a role in preventing adverse outcomes associated with influenza infections. In the US, recent Advisory Committee on Immunization Practices (ACIP) recommendations stipulate that adults aged ≥ 65 years should preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) [39]. Finally, detection and treatment of influenza infection in hospitalizations for respiratory causes, including pneumonia, was found to have benefits in terms of reducing mortality rates in

hospitalized patients [14], with a major increase in the proportion of pneumonia patients who were tested for influenza infection in the US taken place in recent years [14].

Our results have some limitations. Influenza surveillance data in France pertain to mainland France [30], whereas we've used data on mortality for the whole of France. Additionally, sentinel data on testing for viral specimens [31] has a moderate sample size and may not represent all of France. We note that influenza epidemics exhibit a great deal of temporal synchrony [40,41] which should help address the above limitations. Finally, despite the fact that we split some of the influenza subtype incidence indicators into several time periods, there might still be temporal variability in the relation between the incidence indicators used in this paper and rates of associated mortality. For example, while model fits are generally temporally consistent (Figure 1), the model fit for the mortality data for the 2017-2018 season is worse compared to other influenza seasons, which might be related to the fact that the influenza subtypes that circulated during that season (A/H1N1 and B/Yamagata) have different age distributions feeding into one ILI data stream.

Conclusions

The high rates of SARS-CoV-2 associated mortality during the Omicron epidemic that we estimated suggest that increasing booster vaccination coverage for COVID-19 for all adults [3,15], and possibly for children should help mitigate the spread of Omicron infections in the community. Additionally, wider detection and treatment of Omicron infections, particularly in older individuals/persons with underlying health conditions such as cardiac disease and mental/behavioral disorders [7], should help mitigate the mortality burden of future Omicron epidemic waves. For influenza, our results, in combination with data on influenza vaccination coverage in France [18] suggest that boosting influenza vaccination coverage in different population groups (including children [20-22]) and testing for influenza in respiratory illness episodes (including pneumonia) in high-risk individuals during periods of active influenza circulation in combination with the use of antiviral medications is needed to mitigate the mortality burden of influenza epidemics [14]. Finally, very high rates of influenza-associated mortality in individuals aged over 75y during certain influenza seasons in France [42], and the significant increase in COVID-19 related mortality in long-term care facilities for older

individuals in France during the winter of 2022-2023 [9] suggest that additional efforts are needed to better protect those elderly populations during Omicron and influenza epidemics, both in long-term care facilities and in the general community.

References

- [1] Nyberg T, et al. Comparative analysis of the risks of hospitalization and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet* 2022; 399(10332): 1303-1312
- [2] Auvigne V, et al. Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: A retrospective, population-based, matched cohort study. *EClinicalMedicine*. 2022;48:101455
- [3] Santé publique France. Santé publique France. InfoCovidFrance: Chiffres clés et évolution de la COVID-19 en France et dans le Monde. 2022. Available from: <https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde>
- [4] Bouzid D, et al. Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments: A Retrospective Cohort Study. *Ann Intern Med*. 2022;175(6):831-837
- [5] Leiner J, et al. Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. *BMC Infect Dis*. 2022;22(1):802
- [6] de Prost N, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. *Nat Commun*. 2022;13:6025.
- [7] Australian Bureau of Statistics. COVID-19 Mortality by wave. 2023. Available from: <https://www.abs.gov.au/articles/covid-19-mortality-wave>
- [8] Institut national de la statistique et des études économiques (INSEE). Nombre de décès quotidiens France, régions et départements. 2023. <https://www.insee.fr/fr/statistiques/4931039?sommaire=4487854#tableau-figure1>

[9] Institut national de la statistique et des études économiques (INSEE). Daily deaths files broken down by sex, age and place of death.

<https://www.insee.fr/en/statistiques/4493808?sommaire=4493845>

[10] Goldstein E, Viboud C, Charu V, et al. Improving the estimation of influenza-related mortality over a seasonal baseline. *Epidemiology*. 2012;23(6):829-38.

[11] Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018. *JAMA Netw Open*. 2022;5(2):e220527

[12] Quandelacy TM, Viboud C, Charu V, et al. Age- and Sex-related Risk Factors for Influenza-associated Mortality in the United States Between 1997-2007. *Am J Epidemiol*. 2014;179(2):156-67

[13] Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *N Engl J Med*. 2018;378(4):345-353

[14] Deshpande A, Klompas M, Yu P-C, Imrey PB, Pallotta AM, Higgins T, et al. Influenza Testing and Treatment Among Patients Hospitalized With Community-Acquired Pneumonia. *Chest*. 2022;162(3):543-555

[15] Gouvernement de la République française. Vaccins (COVID-19). 2022. Available from: <https://www.gouvernement.fr/info-coronavirus/vaccins>

[16] Chin ET, Leidner D, Lamson L, Lucas K, Studdert DM, Goldhaber-Fiebert JD, et al. Protection against Omicron from Vaccination and Previous Infection in a Prison System. *N Engl J Med*. 2022 Nov 10;387(19):1770-1782

[17] Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. *Nature Medicine* 2023;29:358–365

[18] Robert J, Detournay B, Levant MC, Uhart M, Gourmelen J, Cohen JM. Flu vaccine coverage for recommended populations in France. *Med Mal Infect*. 2020;50(8):670-675

[19] US Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2019–20 Influenza Season. <https://www.cdc.gov/flu/fluview/coverage-1920estimates.htm>

[20] Monto A, Koopman J, Longini IM., Jr Tecumseh study of illness. XIII. Influenza infection and disease, 1976–1981. *Am J Epidemiol*. 1985;102:553–563

[21] Worby CJ, Chaves SS, Wallinga J, Lipsitch M, Finelli L, Goldstein E. On the relative role of different age groups in influenza epidemics. *Epidemics* 2015;13:10-16.

- [22] Cauchemez S, Valleron AJ, Böelle PY, Flahaut A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. *Nature*. 2008;452:750–754.
- [23] Pebody RG, Green HK, Warburton F, et al. Significant spike in excess mortality in England in winter 2014/15 - influenza the likely culprit. *Epidemiol Infect*. 2018;146(9):1106-1113
- [24] Rosano A, Bella A, Gesualdo F, et al. Investigating the impact of influenza on excess mortality in all ages in Italy during recent seasons (2013/14-2016/17 seasons). *Int J Infect Dis*. 2019;88:127-134
- [25] Nielsen J, Vestergaard LS, Richter L, Schmid D, Bustos N, Asikainen T, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? *Clin Microbiol Infect*. 2019 Oct;25(10):1266-1276.
- [26] Editorial. COVID-19 pandemic disturbs respiratory virus dynamics. *The Lancet Respiratory Medicine*. 2022;10(8)725
- [27] Office for National Statistics, UK. Excess deaths in England and Wales: March 2020 to June 2022. 2022. Available from: <https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde>
- [28] Santé Publique France. Bulletin de santé publique canicule. Bilan été 2022. Available from: <https://www.santepubliquefrance.fr/determinants-de-sante/climat/fortes-chaleurs-canicule/documents/bulletin-national/bulletin-de-sante-publique-canicule.-bilan-ete-2022>
- [29] US Centers for Disease Control and Prevention. CDC Wonder mortality data. Available from: <https://wonder.cdc.gov/mcd-icd10-provisional.html>
- [30] Réseau Sentinelles. France. Surveillance continue n.d. 2022. <https://www.sentiweb.fr/france/fr/?page=table> (Accessed on Nov. 2022)
- [31] World Health Organization. Influenza Virus Detections reported to FluNET. 2022. <https://app.powerbi.com/view?r=eyJrIjoiNjViM2Y4NjktMjJmMC00Y2NjLWFmOWQtODQ0NjZkNWY1YzNmIiwidCI6ImY2MTBjMGI3LWJkMjQ0NGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsmMiOjh9>
- [32] Institut national de la statistique et des études économiques (INSEE). Évolution et structure de la population. 2022. Available from: <https://www.insee.fr/fr/statistiques?debut=0&theme=1>
- [33] The Institut national de la santé et de la recherche médicale (INSERM). Données sur la Covid-19 du centre d'épidémiologie sur les causes médicales de décès de l'Inserm. 2022. Available from: <https://opendata.idf.inserm.fr/cepidc/covid-19/telechargements>

- [34] Skowronski DM, et al. (2016) A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season. *Clin Infect Dis.*;63(1):21-32
- [35] Kissling E, Pozo F, Buda S, Vilcu A, Gherasim A, Brytting M, et al. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort. *Euro Surveill.* 2019;24(48).
- [36] Santé publique France. Données hospitalières relatives à l'épidémie de COVID-19. Available from: <https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/>
- [37] Santé publique France. Bulletin épidémiologique grippe, semaine 15. Saison 2022-2023. 2023. <https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/bulletin-epidemiologique-grippe-semaine-15.-saison-2022-2023>
- [38] US Centers for Disease Control and Prevention. Past Seasons Vaccine Effectiveness Estimates. Available from: <https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html>
- [39] US Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season. 2022. https://www.cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm?s_cid=rr7101a1_w
- [40] Schanzer DL, Langley JM, Dummer T, et al. The Geographic Synchrony of Seasonal Influenza A Waves across Canada and the United States. *PLoS One* 2011; 6(6): e21471
- [41] Morris SE, Freiesleben de Blasio D, Viboud C, et al. Analysis of multi-level spatial data reveals strong synchrony in seasonal influenza epidemics across Norway, Sweden, and Denmark. *PLoS One.* 2018 May;13(5):e0197519
- [42] Santé publique France. Bulletin épidémiologique hebdomadaire. Oct. 21, 2019. http://beh.santepubliquefrance.fr/beh/2019/28/pdf/2019_28_1.pdf